Recombinant interleukin-2 in metastatic renal cell carcinoma—A European multicentre phase II study
- 31 December 1991
- journal article
- clinical trial
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 27 (12), 1583-1589
- https://doi.org/10.1016/0277-5379(91)90419-e
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer PatientsAnnals of Surgery, 1989
- Clinical immunotherapy studies in the surgery branch of the U.S. National Cancer Institute: brief reviewCancer Treatment Reviews, 1989
- Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.Journal of Clinical Oncology, 1989
- Metastatic Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer CellsAnnals of Internal Medicine, 1988
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.The Journal of Experimental Medicine, 1985
- Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2Science, 1984
- Reporting results of cancer treatmentCancer, 1981
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958